114 related articles for article (PubMed ID: 37725880)
1. Major Histocompatibility Class-I (MHC-I) downregulation in glioblastoma is a poor prognostic factor but not a predictive indicator for treatment failure.
Butt NS; Kurdi M; Fadul MM; Hakamy S; Addas BMJ; Faizo E; Alkhayyat S; Bamaga AK; Alsinani T; Katib Y; Okal F; Maghrabi Y; Sabbagh AJ; Moshref R; Albalawi S; Alkhotani A; Mohammed F; Mulla N; Baeesa S
Pathol Res Pract; 2023 Oct; 250():154816. PubMed ID: 37725880
[TBL] [Abstract][Full Text] [Related]
2. The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.
Butt N; Enani M; Alshanqiti M; Alkhotani A; Alsinani T; Karami MM; Fadul MM; Almansouri M; Hassan A; Baeesa S; Bamaga AK; Alkhayyat S; Faizo E; Kurdi M
Folia Neuropathol; 2023; 61(3):317-325. PubMed ID: 37818692
[TBL] [Abstract][Full Text] [Related]
3. The synergistic effect of IDH mutation and NDRG-2 dysregulation in the progression of WHO-grade 4 astrocytomas.
Kurdi M; Fadul MM; Alkhayyat S; Sabbagh AJ; Alsinani T; Alkhotani A; Mulla N; Mehboob R; Fathaddin AA; Bamaga A; Faizo E; Baeesa S
Pathol Res Pract; 2023 Aug; 248():154733. PubMed ID: 37536020
[TBL] [Abstract][Full Text] [Related]
4. The effect of p53 on the activity of NRF2 and NDRG2 genes through apoptotic pathway in IDH-wildtype glioblastoma.
Kurdi M; Baeesa S; Fadul MM; Alkhotani A; Alkhayyat S; Karami MM; Alsinani T; Katib Y; Fathaddin AA; Faizo E; Lary AI; Almansouri M; Maghrabi Y; Alyousef MA; Addass B
Pathol Res Pract; 2024 Feb; 254():155118. PubMed ID: 38241776
[TBL] [Abstract][Full Text] [Related]
5. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
[TBL] [Abstract][Full Text] [Related]
6. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA; Messersmith H; Gatson NT; Hottinger AF; Lassman A; Morton J; Ney D; Nghiemphu PL; Olar A; Olson J; Perry J; Portnow J; Schiff D; Shannon A; Shih HA; Strowd R; van den Bent M; Ziu M; Blakeley J
J Clin Oncol; 2022 Feb; 40(4):403-426. PubMed ID: 34898238
[TBL] [Abstract][Full Text] [Related]
7. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
[TBL] [Abstract][Full Text] [Related]
9. Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.
Álvarez-Torres MDM; Fuster-García E; Juan-Albarracín J; Reynés G; Aparici-Robles F; Ferrer-Lozano J; García-Gómez JM
BMC Cancer; 2022 Jan; 22(1):40. PubMed ID: 34991512
[TBL] [Abstract][Full Text] [Related]
10. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
[TBL] [Abstract][Full Text] [Related]
11.
Yoon BH; Park JS; Kang S; Kwon NJ; Lee KS; Kim CY; Choe G
Br J Neurosurg; 2023 Oct; 37(5):1233-1236. PubMed ID: 33095064
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype).
Kessler R; Fleischer M; Springsguth C; Bigl M; Warnke JP; Eschrich K
J Neuropathol Exp Neurol; 2019 Sep; 78(9):865-870. PubMed ID: 31369092
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
14. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
15. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
[TBL] [Abstract][Full Text] [Related]
16. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
18. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
19. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
Lee D; Riestenberg RA; Haskell-Mendoza A; Bloch O
J Neurooncol; 2021 Mar; 152(1):89-98. PubMed ID: 33389563
[TBL] [Abstract][Full Text] [Related]
20. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
